Table 1

Biologicals and targets that are used or potentially may be used in primary Sjögren's syndrome

Target

Biological

Structure

Results trials

References


TNFα

Infliximab

Chimeric IgG1 mAb

No effect in RCT

[15]

TNFα

Etanercept

TNF-Rec1-Fc IgG1 fusion protein

No effect in (small-size) RCT

[17,18]

IFNα

Recombinant IFNα2a

Increase in unstimulated whole saliva flow (RCT)

[32]

IFNα

Rontalizumab

Recombinant human mAb

Not performed

CD20 B cells

Rituximab

Chimeric IgG1 mAb

Subjective and objective improvement of salivary flow (RCT), decrease in fatigue (RCT)

[39,40]

CD22 B cells

Epratizumab

Recombinant human mAb

Increase in unstimulated whole saliva, decrease in fatigue

[45]

BAFF

Belimumab

Recombinant human mAb

In progress

BAFF

Atacicept

TACI-Fc IgG1 fusion protein

Not performed

BAFF

Briobacept

BAFF-Rec-Fc IgG1 fusion protein

Not performed

CD28-mediated

co-stimulation

Abatacept

CTLA4-Fc IgG1 fusion protein

In progress


BAFF, B-cell activating factor; CTLA4, cytotoxic T-lymphocyte antigen 4; mAb, monoclonal antibody; RCT, randomized controlled trial; Rec, receptor; TACI, transmembrane activator and calcium-modulating cyclophilin ligand interactor.

Kallenberg et al. Arthritis Research & Therapy 2011 13:205   doi:10.1186/ar3234